Allogene Therapeutics (ALLO) Insider & Congress Trades

Smart money at a glance

Filings to Nov 14, 2026

Net selling: insiders sold $112K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$112K net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 3 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about ALLO filings

Are insiders buying or selling Allogene Therapeutics Inc (ALLO) stock?

Net selling: insiders sold $112K and bought $0 of ALLO stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. The largest was Douglas, Earl Martin (SVP, General Counsel), who sold $63K. The latest filing was on Oct 23, 2026.

Which members of Congress have traded ALLO recently?

None. No member of Congress disclosed a ALLO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ALLO smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on ALLO

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
- Geoffrey M. Parker, sold $48.7K, open market, filed Oct 23
- Earl Martin Douglas, sold $63K, open market, filed Aug 25
Lean short · thin2 sales · $112K
Form 4 filings, open market.
Congress
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ALLO filings

Are insiders buying or selling Allogene Therapeutics Inc (ALLO) stock?

Which members of Congress have traded ALLO recently?

None. No member of Congress disclosed a ALLO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ALLO smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$55.7M

Buys/Adds (3)

FM
FMR LLC
Q2 2026 13F
$21.1M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
SS
State Street
Q2 2026 13F
$18.4M
added
BR
BlackRock
Q2 2026 13F
$16.1M
added

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 6.5% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.15-6.50% miss

-$0.14 expected

Revenue

$0.00

SEC filing

EPS: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	-$0.15est. -$0.14	-6.50%miss	$0.00SEC filing	No year-ago quarter
Jun 30, 2026Reported Aug 12, 2026	-$0.13est. -$0.15	+12.16%beat	$4.6MSEC filing	No year-ago quarter
Mar 31, 2026Reported May 13, 2026	-$0.18est. -$0.18	+0.00%in line	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Mar 12, 2026	-$0.17est. -$0.22	+22.46%beat	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 6, 2025	-$0.19est. -$0.23	+17.39%beat	$0.00SEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 13, 2025	-$0.22est. -$0.27	+18.52%beat	$0.00SEC filing	No year-ago quarter
Mar 31, 2025Reported May 13, 2025	-$0.28est. -$0.29	+3.45%beat	$0.00SEC filing	-100.0%from $22.0K
Dec 31, 2024Reported Mar 13, 2025	-$0.28est. -$0.32	+13.42%beat	$22.0K · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $0.89
High: $0.90
Low: $0.82
Prev close: $0.90
52-wk high: $4.46
52-wk low: $0.82
Mkt cap: $286.5M
ROE: -49.3%
Beta: 0.78
P/S: 61.8x
P/B: 0.8x
Profit margin: +0.0%
Op margin: -4173.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $287M

Valuation

P/S61.75
P/B0.79

Quality

Operating margin-4173.0%
ROE-49.3%
ROA-25.5%

Growth

Beta0.78

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

25oversold

20D volatility

80%annualized

52-week range

$0.83

$0.82$4.46

20D support

$0.82recent floor

20D resistance

$1.38recent ceiling

Returns

5D -24.1%20D -38.3%60D -62.9%

Price vs moving averages

SMA20 -28.7%SMA50 -42.4%SMA200 -57.7%

Volume pace

1.82xvs prior 20D

Smart money at a glance

Filings to Nov 14, 2026

Net selling: insiders sold $112K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$112K net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 3 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about ALLO filings

Are insiders buying or selling Allogene Therapeutics Inc (ALLO) stock?

Which members of Congress have traded ALLO recently?

None. No member of Congress disclosed a ALLO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ALLO smart-money data?

13F: filed up to 45 days late.

Smart money on ALLO

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
- Geoffrey M. Parker, sold $48.7K, open market, filed Oct 23
- Earl Martin Douglas, sold $63K, open market, filed Aug 25
Lean short · thin2 sales · $112K
Form 4 filings, open market.
Congress
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ALLO filings

Are insiders buying or selling Allogene Therapeutics Inc (ALLO) stock?

Which members of Congress have traded ALLO recently?

None. No member of Congress disclosed a ALLO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ALLO smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$55.7M

Buys/Adds (3)

FM
FMR LLC
Q2 2026 13F
$21.1M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
SS
State Street
Q2 2026 13F
$18.4M
added
BR
BlackRock
Q2 2026 13F
$16.1M
added

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 6.5% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.15-6.50% miss

-$0.14 expected

Revenue

$0.00

SEC filing

EPS: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	-$0.15est. -$0.14	-6.50%miss	$0.00SEC filing	No year-ago quarter
Jun 30, 2026Reported Aug 12, 2026	-$0.13est. -$0.15	+12.16%beat	$4.6MSEC filing	No year-ago quarter
Mar 31, 2026Reported May 13, 2026	-$0.18est. -$0.18	+0.00%in line	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Mar 12, 2026	-$0.17est. -$0.22	+22.46%beat	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 6, 2025	-$0.19est. -$0.23	+17.39%beat	$0.00SEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 13, 2025	-$0.22est. -$0.27	+18.52%beat	$0.00SEC filing	No year-ago quarter
Mar 31, 2025Reported May 13, 2025	-$0.28est. -$0.29	+3.45%beat	$0.00SEC filing	-100.0%from $22.0K
Dec 31, 2024Reported Mar 13, 2025	-$0.28est. -$0.32	+13.42%beat	$22.0K · FYSEC filing	No year-ago quarter

Open: $0.89
High: $0.90
Low: $0.82
Prev close: $0.90
52-wk high: $4.46
52-wk low: $0.82
Mkt cap: $286.5M
ROE: -49.3%
Beta: 0.78
P/S: 61.8x
P/B: 0.8x
Profit margin: +0.0%
Op margin: -4173.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $287M

Valuation

P/S61.75
P/B0.79

Quality

Operating margin-4173.0%
ROE-49.3%
ROA-25.5%

Growth

Beta0.78

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

25oversold

20D volatility

80%annualized

52-week range

$0.83

$0.82$4.46

20D support

$0.82recent floor

20D resistance

$1.38recent ceiling

Returns

5D -24.1%20D -38.3%60D -62.9%

Price vs moving averages

SMA20 -28.7%SMA50 -42.4%SMA200 -57.7%

Volume pace

1.82xvs prior 20D

Allogene Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about ALLO filings

Smart money on ALLO

Questions about ALLO filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 6.5% below what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Allogene Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about ALLO filings

Smart money on ALLO

Questions about ALLO filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 6.5% below what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Allogene Therapeutics Inc

Overview

Questions about ALLO filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Allogene Therapeutics Inc

Overview

Questions about ALLO filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.